Compare MBRX & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBRX | TRIB |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 14.2M |
| IPO Year | 2016 | 1996 |
| Metric | MBRX | TRIB |
|---|---|---|
| Price | $2.67 | $0.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | 409.6K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.51 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.31 |
| 52 Week High | $7.98 | $3.44 |
| Indicator | MBRX | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 30.21 |
| Support Level | $2.12 | N/A |
| Resistance Level | $2.72 | $0.77 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 23.88 | 12.23 |
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.